Treatment of lung carcinoma cell lines with rosiglitazone decreased proliferation via PPARγ-dependent upregulation of PTEN and inhibition of Akt activity, and also via PPARγ-independent inhibition of the mTOR pathway [195, 196]. Here, PPARG is linked to lung carcinoma.